Author

Grygorii Ursol

Observed name: Ursol Grygorii

Observed institution: Instituto Nacional de Câncer - INCA

OpenAlex ID: A5009341892

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

2019 · Luis Paz-Ares, Mikhail Dvorkin, et al. · The Lancet · 2,281

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

2020 · Javier Cortes, David W Cescon, et al. · The Lancet · 1,797

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

2020 · Jonathan W Goldman, Mikhail Dvorkin, et al. · The Lancet Oncology · 688

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study

2022 · Melissa L. Johnson, Byoung Chul Cho, et al. · Journal of Clinical Oncology · 455

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

2024 · B. Sangro, S.L. Chan, et al. · Annals of Oncology · 357

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)

2021 · Dmytro Trukhin, Elena Poddubskaya, et al. · BioDrugs · 27

A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.

2022 · Enriqueta Felip, Margarita Majem, et al. · Journal of Clinical Oncology · 25

A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study

2024 · Edward B. Garon, Byoung Chul Cho, et al. · Clinical Lung Cancer · 15

Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)

2023 · Edward B. Garon, Byoung Chul Cho, et al. · Lung Cancer · 12

1470 Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II)

2022 · Wade Iams, Enriqueta Felip, et al. · 3

Clinical efficacy and safety of the BAT1706 (proposed bevacizumab biosimilar) compared with reference bevacizumab in patients with advanced nonsquamous NSCLC: A randomized, double-blind, phase III study.

2022 · Likun Chen, Dmytro Trukhin, et al. · Journal of Clinical Oncology · 3

Corrigendum to ‘MA04.04 Perioperative Pembrolizumab in Non-Small Cell Cancer (NSCLC): 4-Year Outcomes by Nodal Status in the KEYNOTE-671 Study’ [Journal of Thoracic Oncology Volume 20 Issue 10 Supplement 1 (2025) S67]

2026 · Heather A. Wakelee, Ingel Demedts, et al. · Journal of Thoracic Oncology

595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab

2023 · Martin Forster, Enriqueta Felip, et al. · Regular and Young Investigator Award Abstracts

Association Between Kras/stk11/keap1 Mutations and Outcomes in Patients From the Poseidon Study: Durvalumab ± Tremelimumab + Chemotherapy in Mnsclc

2022 · Luiz Henrique Araujo, Solange Peters, et al. · Brazilian Journal of Oncology

Durvalumab (D) +/- tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON.

2022 · Byoung Chul Cho, Niels Reinmuth, et al. · Journal of Clinical Oncology

Works count: 15

Citation count: 5,657

H-index: 9

I10-index: 9